Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this project is to investigate whether the proliferative speeds of cultured cells using our method can be integrated into Barcelona Clinic Liver Cancer (BCLC) staging classification for the possibility of personalized treatment and prediction the outcomes in hepatocellular carcinoma (HCC) patients.

Detailed Description
-----------------
A total of at least 150 patients will be included and followed for at least one year. The proliferative speeds of cultured cells will be classified into (a) rapid proliferation of HCC cells with or without concomitant rapid proliferation of cancer-associated fibroblasts (CAFs), (b) rapid proliferation of CAFs alone, and (c) slow proliferation three groups. The definition for the rapid proliferation of cultured cells fits at least one of the following two items: (1) growth area of cultured cells at the 15th-28th day > two times of the growth area measured at the 14th day, or (2) growth area of cultured cells at the 15th-28th day > 70% growth area of the 25 cm flask. The GraphPad Prism software version 4.03 (GraphPad Software, Inc., La Jolla, CA, USA) is applied for statistical analysis. Influence of the proliferative speeds of cultured cells on survival and cancer progression will be calculated by the logrank test. The statistical significance is defined as P < 0.05.

Official Title
-----------------
Kaohsiung Medical University Chung-Ho Memorial Hospital

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Other: not interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients are proven to have HCC based on fine-needle aspiration of the tumor. Patient have residual specimens obtained from fine-needle aspiration of the tumor. Patients agree to participate this study after fully explanation. Exclusion Criteria: Patients are not proven to have HCC based on fine-needle aspiration of the tumor. Patient do not have residual specimens obtained from fine-needle aspiration of the tumor. Patients do not agree to participate this study after fully explanation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Barcelona Clinic Liver Cancer (BCLC) staging<br>The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D. | Other: not interventional study<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival | Correlation between the proliferative speeds of cultured cells and one year survival of the patients after aspiration of the tumor will be investigated. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cancer progression | Correlation between the proliferative speeds of cultured cells and HCC progression one year after aspiration of the tumor will be investigated. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatocellular Carcinoma, primary culture, fine-needle aspiration, cancer-associated fibroblast